Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, a biotechnology firm listed under NASDAQ: CRIS, will present a company overview at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 11:00 a.m. in New York. James Dentzer, President and CEO, will lead the presentation. A live webcast will be available on the Curis website, with a replay accessible for 90 days post-event. Curis focuses on cancer therapeutics, holding licenses for various innovative treatments, including emavusertib, currently in clinical trials, despite a partial hold by the FDA on certain trials. For more details, visit www.curis.com.
Curis (NASDAQ: CRIS) announces the upcoming presentations of multiple abstracts at the European Hematology Association 2022 Hybrid Congress from June 9-12, 2022, in Vienna. Key data from the TakeAim Lymphoma trial shows early anti-cancer activity with emavusertib combined with ibrutinib in heavily pretreated patients, including one complete response and two partial responses. Additionally, relevant insights from the TakeAim Leukemia study will also be shared. The company highlights the need for new treatment options for patients with resistant hematologic cancers.
Curis, a biotech firm, reported a net loss of $16.1 million for Q1 2022, compared to a loss of $9.9 million in Q1 2021. Revenues remained stable at $2.1 million. The company has a strong balance sheet with $120.7 million in cash, allowing operations to continue into 2024. Clinical updates include promising data for emavusertib, an IRAK4 inhibitor, though FDA has placed a partial hold on two studies. Initial safety data for CI-8993, an anti-VISTA antibody, were also discussed.
Curis, Inc. (NASDAQ: CRIS) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. market close. A conference call is scheduled for the same day at 4:30 pm ET. The call can be accessed by dialing (888) 346-6389 in the U.S. or (412) 317-5252 internationally, and will also be available on Curis's website. Curis focuses on developing cancer therapeutics and has ongoing collaborations with Aurigene, ImmuNext, and Genentech.
Curis, Inc. (NASDAQ: CRIS) announced a partial clinical hold placed by the FDA on its TakeAim Lymphoma study for emavusertib. This follows an earlier hold on the TakeAim Leukemia study, affecting patient enrollment in both studies. Current participants can continue treatment at specified doses, pending reconsent. The FDA requests additional data on safety and efficacy related to emavusertib, including specific safety concerns. Curis aims to resolve this hold and is optimistic about the potential of emavusertib to address unmet needs in B-cell cancers.
Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options for 380,850 shares to seven new employees, effective April 1, 2022. Each option has an exercise price equal to the April 1 closing price and a 10-year term, vesting over four years. This move aims to attract talent critical to Curis's innovative cancer therapeutics development. Curis is also involved in several collaborations, testing new cancer treatments, although the FDA has placed a partial hold on one of its trials.
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focusing on cancer therapeutics, will have its CEO James Dentzer present at the 21st Annual Needham Virtual Healthcare Conference. This presentation will be available for on-demand viewing starting April 12, 2022, at 8:45 a.m. ET. Investors can access a live webcast on the company's website, with a replay available for 90 days post-event. Curis is known for its collaborations in immuno-oncology and its ongoing clinical trials for therapies like emavusertib, aimed at non-Hodgkin's lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) announced a partial clinical hold by the FDA on its TakeAim Leukemia Phase 1/2a study due to safety concerns, particularly related to a patient fatality involving rhabdomyolysis, a known toxicity of emavusertib (CA-4948). While no new patients will be enrolled during this hold, current participants may continue treatment with lower doses. The FDA requires additional data on safety and efficacy before the study can resume. This hold does not affect the TakeAim Lymphoma study, but Curis has paused enrollment in that trial as well.
Curis, Inc. (NASDAQ: CRIS) announced the publication of a manuscript in Gastroenterology, detailing the role of IRAK4 in pancreatic ductal adenocarcinoma (PDAC) and the preclinical efficacy of the IRAK4 inhibitor emavusertib (CA-4948) combined with checkpoint immunotherapy. The study indicates that targeting IRAK4 could counteract tumor-induced T-cell exhaustion and improve responses to treatment. The research suggests potential broader applications of emavusertib in solid tumors, highlighting its promise in addressing significant unmet patient needs in cancer therapeutics.
Curis, Inc. (NASDAQ: CRIS) reported its Q4 2021 financial results, showing a net loss of $13.6 million or $0.15 per share, compared to a net loss of $7.5 million in Q4 2020. Total revenues for 2021 were $10.6 million, slightly down from $10.8 million in 2020. Notably, Curis announced promising clinical progress in its pipeline, particularly for emavusertib (CA-4948) in leukemia treatment, and favorable safety data for CI-8993. The company plans to discuss a rapid FDA registration path and continues to see operational growth with new executive appointments.